Whether you’re developing a vaccine—therapeutic and/or prophylactic—a cytotoxic agent, a molecule intended for targeted replacement in specific cells or tissues, or a bi-specific T-cell engager, the Serendip platform can support your goals.

Our technology is particularly well suited for immuno-oncology applications. The ability to target specific immune cell subtypes and deliver tumor antigens positions VLPs as a strong candidate for effective immunization strategies. This targeted approach is designed to activate the immune system specifically against tumor cells, enabling their selective destruction.

An effective immunization platform is especially valuable for therapeutic cancer vaccines, aimed at eliminating residual cancer cells and reducing the risk of relapse. In many cancer indications, these residual cells evade current immunotherapies and chemotherapies, often remaining undetectable and leading to recurrence.